Strategies for Relapsed Peripheral T-Cell Lymphoma: The Tail That Wags the Curve
نویسندگان
چکیده
منابع مشابه
Peripheral T-cell Lymphoma of the Uvula: A Rare Entity
Abstract Introduction: Extra-nodal exposition of T-cell non-hodgkin lymphoma (NHL) is extremely rare, and is frequently observed in patients with immune system dysfunction. Peripheral T-cell lymphoma does not express CD56 is rare. Malignant lymphoma of the uvula is exceedingly unusual. The current study reported a case of peripheral T-cell lymphoma of the uvula in an immunecompetent patient. ...
متن کاملPeripheral T-cell Lymphoma of the Uvula: A Rare Entity
Abstract Introduction: Extra-nodal exposition of T-cell non-hodgkin lymphoma (NHL) is extremely rare, and is frequently observed in patients with immune system dysfunction. Peripheral T-cell lymphoma does not express CD56 is rare. Malignant lymphoma of the uvula is exceedingly unusual. The current study reported a case of peripheral T-cell lymphoma of the uvula in an immunecompetent patient. ...
متن کاملThe Tail that Wags the Dog
Tails are of paramount importance in shaping the risk profile of portfolios with credit risk sensitive securities. In this context risk management tools require simulations that accurately capture the tails, and optimization models that limit tail effects. Ignoring the tails in the simulation or using inadequate optimization metrics can have significant effects and destroy portfolio efficiency....
متن کاملBelinostat for Relapsed or Refractory Peripheral T-Cell Lymphoma
Peripheral T-cell lymphomas (PTCLs) represent an uncommon heterogenous group of neoplasms that make up approximately 10% to 15% of non-Hodgkin lymphomas. PTCL, not otherwise specified (NOS) is the most common form, whose incidence in the United States has been increasing, possibly due to better diagnostic methods. PTCLs represent a rare and aggressive subgroup of NHLs that do not respond favora...
متن کاملPeripheral T-cell lymphoma: new therapeutic strategies.
Between 2006 and 2011, four new agents gained regulatory approval for the treatment of relapsed/refractory cutaneous T-cell lymphoma (CTCL) and peripheral T-cell lymphoma (PTCL). These new approvals, together with recent advances in both combination chemotherapy and transplant strategies, have made the landscape for treatment of these patients immensely complex. Multiple clinical trials are now...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Clinical Oncology
سال: 2013
ISSN: 0732-183X,1527-7755
DOI: 10.1200/jco.2012.48.3883